Track topics on Twitter Track topics that are important to you
How Two Common Medications Became One $455 Million Specialty PillMarshall Allen (The Atlantic) The Startling History Behind Merck's New Cancer BlockbusterDavid Shaywitz (Forbes) Conquering HIV’s capsid: After a dozen years, researchers have struck upon a molecule that can disrupt an elusive HIV targetLisa Jarvis (Chemistry & Engineering News) Birth of CRISPR’d pigs advances hopes for turning swine into organ donorsSharon Begley (STAT News) Opinionome: The past [...]
Original Article: End of Summer Biotech Reading ListNEXT ARTICLE
Alliances Astrazeneca Bioethics Boehringer Clinical Research Organization Collaborations GSK Johnson & Johnson Lilly Merck Mergers and Acquisitions Nexium Novartis Pfizer Roche Sanofi ...
Bladder Cancer Brain Cancer Breast Cancer Cancer Cervical Cancer Colorectal Head & Neck Cancers Hodgkin Lymphoma Leukemia Lung Cancer Melanoma Myeloma Ovarian Cancer Pancreatic Cancer ...